CAR NK biotech Catamaran Bio to wind down, will seek partners for cell therapies

Off-the-shelf cell ther­a­py biotech Cata­ma­ran Bio made a “re­cent de­ci­sion to com­mence wind-down,” CEO Alvin Shih told End­points News in an email on Mon­day.

The Boston biotech will cease day-to-day op­er­a­tions and seek strate­gic part­ners for its CAR NK cell ther­a­py can­di­dates and tech­nol­o­gy, Shih wrote in a LinkedIn post on Mon­day. Cata­ma­ran had 19 em­ploy­ees as of Mon­day morn­ing, he told End­points, and a “hand­ful” will stay on for a tran­si­tion pe­ri­od.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.